Furthermore, LSM2 expression was significantly higher in gliomas with 1p/19q non-deletion (494 cases) than in those with 1p/19q co-deletion (169 cases) (p < 0.001), as well as in IDH1-mutant gliomas (429 cases) compared to IDH1 wild-type cases (233 cases) (p < 0.001) (Figures 2C, D). The gene discussed is LSM2; the disease is central nervous system cancer.